Date: 2016-10-11
Type of information: Nomination
Compound:
Company: Curevac (Germany)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 11, 2016, CureVac announced the appointment of Pierre Kemula as Chief Financial Officer (CFO). Mr. Kemula will join CureVac’s management board and will be responsible for leading the company’s financial and capital markets activities. Mr. Kemula joins CureVac after serving as Chief Financial Officer of Pixium Vision, a medical technology company developing innovative Bionic Vision Systems to provide a form of vision to blind patients suffering from outer retinal degeneration. During his tenure as CFO of Pixium Vision, Mr. Kemula was instrumental in the company’s successful initial public offering on Euronext. Prior to Pixium Vision, Mr. Kemula was with Ipsen, a global specialty-driven pharmaceutical company, where he held the position of Vice President Corporate Finance, Treasury and Financial Markets. Mr. Kemula began his career in consulting, with successful tenures at Roland Berger, Kea & Partners, Gemini Consulting and KPMG. He received his degree in Management Sciences from the London School of Economics (LSE) in the United Kingdom.
Financial terms:
Latest news:
